Mnpc Antiviral Etc

Front 1

amantadine
rimantadine

Back 1

inhibit M2 channels required for uncoating. interfere with viral disassembly to nucleus during invasion of host cells. decr penetration; decr uncoating; decr early stages of replication

Front 2

alpha and beta interferon

Back 2

cytokines, bind on adjacent cells and protect them from infection by viruses.

Front 3

inducers of interferon

Back 3

imiquimod

Front 4

neuraminidase glycoprotein inhibitors MOA

Back 4

unable to cleave sialic acid residues from glycoproteins on the surface of cells. cannot release from infected cells. also cannot move thru mucous.

Front 5

Oseltamivir
Zanamivir

Back 5

oral prodrug
aerosol
mimic NANA, which is cleaved by neuraminidase.

Front 6

agents that interfere with nucleic acid biosynthesis

Back 6

generally classified as anti-herpes agents via either competitive inhib of viral DNA polymerase, chain terminating base, or other effects after incorporation such as structural alteration to DNA

Front 7

acyclovir and ganciclovir

Back 7

incr affinity for viral kinases over mammalian
viral kinase puts 1st P on structure
additional 2 Ps provide analog of NTP
bind DNA polymerase and either competitively inhib DNA polymerase or if incorporated, block chain elongation.

Front 8

cidofovir

Back 8

chain terminator for CMV eye infections in AIDS

Front 9

penciclovir and famciclovir (topical cold sore; oral)

Back 9

competitive inhib or dna polymerase

Front 10

idoxuridine

Back 10

ophthalmic for herpes in eye
compet DNA polymerase inhib
some incorporates and causes breaks/bad transcription

Front 11

sorivudine

Back 11

substrate for viral thymidine kinase
compet inhib of DNA polymerase

Front 12

trifluorothymidine

Back 12

1. phosphorylated-->trapped
2) compet inhib viral DNA polymerase
3) inhib thymidylate synthase in cell (2' action)

Front 13

foscarnet uses

Back 13

CMV in aids
herpes in mucous membr's
IV

Front 14

foscarnet MOA

Back 14

bind to pyrophosphate site on vDNA Polymerase...w/o the req activation by kinases in the prev agents

Front 15

RT inhibitors

Back 15

enter host cell
phosphorylated and trapped
incorp into DNA but block RT b/c they act as chain terminators
NO 3'OH

Front 16

AZT

Back 16

OH-->N3
IV or oral

Front 17

didanosine

Back 17

less potent/toxic than AZT
oral

Front 18

stavudine

Back 18

RT chain term like always, but also more effectively competes w/ deoxythymidine for use by RT by mimicing closer.

Front 19

zalcitabine

Back 19

mimic deoxycytidine

Front 20

lamivudine!!

Back 20

L rather than D sugar (less tox)
good for resistant strains

Front 21

abacavir

Back 21

hydrophobic gp: BBB
combine w/ lamivudine for the resistant's and azt

Front 22

NNRTIs

Back 22

stable, more hydrophobic, better PK and PD
bind adjacent site
BUT high resistance